Ghana is the first country that agreed to use the Oxford vaccine for malaria

A vaccine against malaria from the University of Oxford obtained its first approval in Ghana, which strengthens his efforts to combat mosquitoes and kill a child every minute. This vaccine comes within efforts to focus on the disease that leads to the lives of more than 600,000 people annually, most of their children in Africa. The complex life cycle of the parasite that causes malaria has hampered the efforts to develop vaccines for a long time. After a work that lasted decades, the first malaria vaccine, the British pharmaceutical company “GLC”, received the approval of the World Health Organization last year, but the lack of financing and commercial opportunities hampered the company’s ability to produce the necessary doses. The Oxford vaccine has approved the regulatory authorities for the age group most vulnerable to malaria, which is children between five months and 36 months. Doses to save 25 million children and the vaccine has an advantage in manufacturing thanks to an agreement with the Serum Institute in India to produce up to 200 million doses annually. On the other hand, GSC delivered to 15 million doses of the MusicirX vaccine annually, much less than 100 million doses annually of the fourth vaccine that, according to the World Health Organization, is needed in the long run to enough. Adrian Hill, the world in Oxford, said this is the first time a major vaccine in an African country has only been approved in front of the rich countries, pointing out that it is not customary for an organizational body in Africa to review the data faster than the World Health Organization. He added: “Especially after Kofid, the African regulatory authorities have taken a more proactive position. They say … we don’t want to be at the end of the class.” Also read: